News/ News/ R&D Takeda’s Ninlaro fails phase 3 amyloidosis trial George Underwood amyloidosis, Ninlaro, Takeda 0 Comment Takeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not Share X Takeda’s Ninlaro fails phase 3 amyloidosis trial https://pharmaphorum.com/news/takedas-ninlaro-fails-phase-3-amyloidosis-trial/
